-9.
306. Rabe E, Stucker M, Esperester A, Schafer E, Ottillinger B. Efﬁcacy
and tolerability of a red-vine-leaf extract in patients suffering from
chronic venous insufﬁciency–results of a double-blind placebocontrolled study. Eur J Vasc Endovasc Surg 2011;41:540-7.
307. Azhdari M, Zilaee M, Karandish M, et al. Red vine leaf extract (AS 195)
can improve some signs and symptoms of chronic venous insufﬁciency, a systematic review. Phytother Res 2020;34:2577-85.
308. Shevchenko Y, Stojko Y, Yashkin M, Chernyago T. Functional features of vascular endothelium after endovenous laser tharapy and
pharmacotherapy (sulodexide) in patients with varicose veins with
CEAP clinical class C4. Eur J Vasc Endovasc Surg 2022;54:E43.
309. Gonzalez Ochoa AJ, Carrillo J, Manriquez D, Manrique F,
Vazquez AN. Reducing hyperpigmentation after sclerotherapy: a
randomized clinical trial. J Vasc Surg Venous Lymphat Disord
2021;9:154-62.

Submitted Jul 14, 2023; accepted Aug 20, 2023.

Additional material for this article may be found online
at www.jvsvenous.org.

65.e1

Gloviczki et al

Journal of Vascular Surgery: Venous and Lymphatic Disorders
January 2024

APPENDIX (online only).
1. VADs for CVD
This section reviews brieﬂy the scientiﬁc evidence supporting the clinical beneﬁt of Hydroxyethylrutosides, calcium dobesilate, Horse chestnut extract, Red vine leaf
extract and Sulodexide for patients with varicose veins
and CVD. None of these products are approved by the
US Food and Drug Administration for use in patients
with venous disease.
Clinical